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Abstract 1 
The current study was carried out in central and North-western parts of Ethiopia to assess the 2 
efficacy of Kenyan sheep pox virus strain vaccine (KS1 O-180) against natural lumpy skin 3 
disease (LSD) infection under field conditions by estimating its effect on the transmission and 4 
severity of the disease. For this study, an LSD outbreak was defined as the occurrence of at least 5 
one LSD case in a specified geographical area. An observational study was conducted on a total 6 
of 2053 (1304 vaccinated and 749 unvaccinated) cattle in 339 infected herds located in 10 sub-7 
kebeles and a questionnaire survey was administered to 224 herd owners. Over 60% of the herd 8 
owners reported that the vaccine has a low to very low effect in protecting animals against 9 
clinical LSD; almost all of them indicated that the vaccine did not induce any adverse reactions. 10 
In the unvaccinated group of animals 31.1% were diagnosed with LSD while this was 22.5% 11 
in the vaccinated group (P<0.001). Severity of the disease was significantly reduced in 12 
vaccinated compared to unvaccinated animals (OR = 0.68, 95% CI: 0.49; 0.96). Unvaccinated 13 
infected animals were more likely (predicted fraction=0.89) to develop moderate and severe 14 
disease than vaccinated infected animals (predicted fraction=0.84).  15 
LSD vaccine efficacy for susceptibility was estimated to be 0.46 (i.e. a susceptibility effect of 16 
0.54) while the infectiousness effect of the vaccine was 1.83. In other words, the vaccine 17 
reduces the susceptibility by a factor of two and increases infectiousness by approximately the 18 
same amount. LSD transmission occurred in both vaccinated and unvaccinated animals, the 19 
estimated reproduction ratio (R) was 1.21 in unvaccinated animals compared to 1.19 in 20 
vaccinated ones, and not significantly different. In conclusion, KS1 O-180 vaccination, as 21 
applied currently in Ethiopia, has poor efficacy in protecting cattle populations against LSD, 22 
neither by direct clinical protection nor by reducing transmission, and this signifies the urgent 23 
need to either improve the quality of the vaccine or to develop potent alternative vaccines that 24 
will confer good protection against LSD. 25 
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1. Introduction 29 
Lumpy skin disease (LSD) is a disease of cattle caused by LSD virus, a DNA virus, which 30 
belongs to the family Poxviridea, subfamily Chordopoxvirinae and it is of the genus 31 
Capripoxvirus. The disease is characterized by fever, nodular lesions on the skin and mucous 32 
membranes, inflammatory and oedematous swellings of the limbs and brisket, 33 
lymphadenopathy, deterioration of body condition and drop in milk production (Davies, 1991; 34 
Quinn et al., 2002; Radostits et al., 2007). It has spread to most African countries, Middle East 35 
countries and recently to Europe (Davies, 1991; Tuppurainen and Oura, 2012; Tasioudi et al., 36 
2016; WAHID, 2016; Tuppurainen et al., 2017). LSD is endemic in Ethiopia and is a constant 37 
threat to the livestock sector since its first occurrence in 1981 (Mebratu et al., 1984; Gari et al., 38 
2010). LSD outbreaks occur frequently in various regional states of the country, despite 39 
intensive vaccination campaigns (APHRD, 2012). It is an economically devastating and 40 
therefore a notifiable disease as per OIE disease categorization (Gari et al., 2011; Tuppurainen 41 
and Oura, 2012; OIE, 2016). 42 
Vaccination, movement control and slaughter of infected and in-contact animals are 43 
considered as options for the control of LSD. However, it is widely agreed that vaccination is 44 
the most manageable and realistic approach to control the disease in endemic and resource poor 45 
countries (Carn, 1993; Tuppurainen et al., 2014). Live attenuated vaccines based on sheep pox 46 
virus (for example, Kenyan sheep pox (KS1 O-180), Romanian sheep pox and Yugoslavian 47 
RM 65 sheep pox vaccines), goat pox virus (Gorgan goat pox vaccine), and LSDV (Neethling 48 
strain vaccine) have been used for the control of LSD (OIE, 2010; Tuppurainen et al., 2014; 49 
Gari et al., 2015).  50 
In general vaccination can exert important effects, both at the individual and at the 51 
population level. It may help to directly protect vaccinated animals, reduce severity of the 52 
disease by reducing all or some of its symptoms or it may reduce transmission of pathogens by 53 
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lowering susceptibility and/or infectiousness, and thus also indirectly reduce the risk for other 54 
vaccinated and unvaccinated individuals to become infected (De Jong, 1994; Halloran et al., 55 
1997; Van der Goot et al., 2007; Aznar et al., 2011; OIE, 2015). The effect of vaccine 56 
intervention on the dynamics of infectious diseases, i.e. in the population, can be estimated by 57 
the reproduction ratio (R) which is the average number of secondary cases arising from one 58 
typically infected animal during its entire infectious period (Diekmann et al., 1990; Heffernan 59 
et al., 2005). 60 
LSD vaccine failure has been reported in several countries including Ethiopia. During 61 
the 2006 outbreak in Israel, 11% (4.2% in dairy and 33.7% in feedlot cattle) of RM65 (Ramayer 62 
strain) vaccinated cattle became infected (Brenner et al., 2009). In Jordan, Abutarbush (2014) 63 
reported an overall LSD morbidity of 4.7% in cattle populations vaccinated with RM65 64 
(Jovivac®) and LSD vaccine of unknown origin. Kumar (2011) reported a continued LSD 65 
outbreak in Oman for more than three months after vaccination of cattle herds with Kenyan 66 
sheep and goat pox vaccine. In Ethiopia, LSD vaccine failure has been reported since 1993 67 
(Carn, 1993). Ayelet et al. (2013) estimated morbidity to be 23.8% in the cattle population of 68 
central Ethiopia after vaccination with KS1 O-180 virus strain vaccine. However, a better 69 
protection was claimed with Neethling vaccine (1.11% morbidity) and with a 10 times higher 70 
dose of the RM65 vaccine (1.85% morbidity) (Ben-Gera et al., 2015). Vaccines in general may 71 
give only partial protection (leaky vaccines) or protect only some of the individuals (all-or-72 
nothing) (Smith et al., 1984). In addition, further immunization failure may arise due to 73 
insufficient vaccine coverage or factors related to the host, vaccine, or vaccination quality due 74 
to handling, reconstitution or administration of the vaccine (Quinn et al., 1999).  75 
Ayelet et al. (2013) and Gari et al. (2015) reported that KS1 O-180 vaccine provides 76 
incomplete protection in immunized animals. However, the level of protection and its effect on 77 
the severity of the disease have not been documented well under field conditions. KS1 O-180 78 
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vaccine is still applied as the sole means of LSD control in Ethiopia. Hence, the aims of this 79 
study was to assess the efficacy of KS1 O-180 virus strain vaccine against natural LSD 80 
infections under field conditions by estimating its effect on the transmission and severity of the 81 
disease.  82 
 83 
2. Materials and Methods 84 
2.1. Study and study area 85 
The study consisted of two parts:  86 
(1) A questionnaire survey focusing on herd owners’ information regarding several aspects 87 
of vaccination which was undertaken in central and North-western parts of Ethiopia 88 
(Figure 1). In central Ethiopia, it was undertaken in Ada’a, Sebeta Hawas, Ambo, Dendi, 89 
Debrelibanos, Kuyu and Hidabu Abote districts in Oromia National Regional State. In 90 
North-western part, the data were collected from Dejen, Gozamen, Hulet Ejju Enessie 91 
and Jabitenan districts in Amhara National Regional State. The dominant agricultural 92 
production system in the study areas was mixed crop-livestock system. The grazing 93 
practice in almost all study areas was open grazing on communal pasture land where 94 
animals from a village were herded together. 95 
(2) A vaccine efficacy follow-up study under field conditions was undertaken in the North-96 
western part of Ethiopia in Mota town and the surrounding four rural kebeles (the lowest 97 
administrative structure in Ethiopia, in which at least 500 households (3,500 to 4,000 98 
persons) live and cover on average about 53 km2 and 3 km2 land area in rural and urban 99 
places, respectively) of Hulet Ejju Enessie district, East Gojjam Administrative Zone, 100 
Amhara National Regional State (Figure 2). The rural kebeles were Hibre Selam, Debre 101 
Gubae, Beza Bizuhan, and Ayen Berhan. Cattle populations of ten sub-kebeles were 102 
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enrolled in the study namely Mota (from Mota town), Akobe, Semo, and Shewaber from 103 
Hibre Selam, Atetanat and Yerez from Beza Bizuhan, Webmariam from Ayen Berhan, 104 
and Kesmender, Komma and Zenabach from Debre Gubae kebele.  105 
2.2. Questionnaire survey 106 
The study population for the questionnaire survey was about 13,200 cattle herd owners living 107 
in 33 selected kebeles of 11 districts. These owners were smallholder farmers with the main 108 
purpose of subsistence farming, that is: draft power for crop production, milk for consumption, 109 
manure for soil fertility and fuel, and cash income. Animals were kept in an extensive 110 
management system and most of the herds were composed of local Zebu breed cattle. Animals 111 
in this system share communal grazing and watering resources. The term “herd” in this study 112 
designates an aggregate of animals kept together day and night and owned by a household.  113 
 114 
2.2.1. Study design and data collection 115 
Eleven districts located in the central and north-western parts of Ethiopia were identified for a 116 
cross-sectional questionnaire survey. The districts were selected based on the recent LSD 117 
outbreak occurrence, location and accessibility. For this study, an LSD outbreak was 118 
considered, if at least one case of LSD occurred in a specified geographical area (usually 119 
kebele). Three kebeles were randomly selected from each district. From each kebele, five to 120 
eight herd owners willing to participate were interviewed. The survey data were collected from 121 
a total of 224 herd owners from January 2015 to May 2015.  122 
The data were collected by face to face interview using the local language. After getting an 123 
informed consent from the herd owners, the interviewer asked questions about the vaccination 124 
status, vaccination frequency, the vaccination service provider, fee of the vaccination, the 125 
vaccination date and when the animals become infected if there was any infected animal in his 126 
herd. Furthermore, the herd owners were requested to express their opinion on the effectiveness 127 
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of the vaccine in protecting cattle against LSD and the adverse reactions to the vaccine. The 128 
vaccine is considered to be protective from day 21 to one year post vaccination. All responses 129 
were recorded in a predesigned response sheet. 130 
 131 
2.2.2. Data management and analysis  132 
Descriptive statistics were used to summarise the data on vaccination coverage at herd level, 133 
frequency of vaccination, and owner’s opinion about the effectiveness and adverse reactions of 134 
the LSD vaccine. 135 
 136 
2.3. Follow-up study 137 
A follow-up study was carried out after the index case of LSD appeared in Beza Bizuhan kebele 138 
at the specific village called Chech on 29 April 2014. The disease stayed restricted in the village 139 
for a reasonable period of time but after that it spread to other villages and surrounding kebeles. 140 
The selected area for follow-up was Mota town and its surrounding area, representing 10 sub-141 
kebeles. In the area, animals were owned by smallholder farmers with the main purpose of 142 
subsistence farming except for six dairy farms which kept cattle for commercial purposes. Most 143 
of the herds were composed of local Zebu breed cattle and managed under extensive 144 
management. The six dairy herds consisted mainly of Holstein-Zebu cross and were managed 145 
under semi-intensive or intensive conditions.  146 
The study population included 7464 heads of cattle grouped in 1203 herds. The cattle 147 
population in each sub-kebele (considered as ten separate populations as they were herded on 148 
common pasture land within a sub-kebele) was vaccinated partially. This partial coverage was 149 
not purposive but due to the failure of the owner to get their animals vaccinated. The vaccination 150 
campaign was undertaken at least one month before the entrance of the disease into a specific 151 
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sub-kebele. The vaccination was provided by the public veterinary service of the Hulet Ejju 152 
Enessie district following the index case appearance in the area.  153 
 154 
2.3.1. Study design and herd selection 155 
This study was designed as a prospective cohort study. At the beginning of the study, ten cattle 156 
populations (i.e. all cattle in a sub-kebele excluding calves less than 6 month old) with partial 157 
vaccination coverage and LSD free status were selected. All herds in the selected populations 158 
were inspected on a weekly basis for clinical signs of LSD. The herd owners were also asked 159 
to report any suspicion of the disease. The sub-kebeles were selected based on their partial 160 
vaccination status. We selected populations with different vaccination coverage because that is 161 
a pre-requisite to estimate both vaccine efficacy for susceptibility and infectiousness (Longini 162 
et al., 1998; Aznar et al., 2011). The vaccination coverage level in the selected 10 sub-kebele 163 
cattle populations ranged from 3-95%. Since the vaccine coverage was strictly inferior to 100%, 164 
a number of infections within the vaccinated group was expected to occur. The animals, whether 165 
vaccinated or not, were followed starting from August 1, 2014 to November 31, 2014, i.e. from 166 
the day the first case was detected in the sub-kebele until no more new cases were recorded. If 167 
an animal in a herd was diagnosed with LSD and the owner volunteered to participate, the herd 168 
was enrolled in the study. Therefore, the main inclusion criteria for a herd were the infection 169 
status of the herd and the willingness of the owner to participate. A herd was considered positive 170 
if at least one animal showed LSD-characteristic nodular lesions. In total, 448 herds were 171 
recorded as being affected and of these, 339 farmers (75.7%) were willing to participate and all 172 
their bovines (n=2053) enrolled in the study.  173 
 174 
2.3.2. Data collection 175 
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In the ten sub-kebeles, infected herds were visited twice a week by animal health professionals 176 
and by the first author, and clinical signs were recorded. The severity of LSD was assessed at 177 
three levels: mild, moderate and severe. Mild LSD was defined as only few nodular lesions (<5) 178 
in some part of the body, mild fever (39-39.50C) and quick recovery (within a week); the 179 
moderate level was assigned if fever, inappetence, many nodular lesions/swelling on the limb 180 
or brisket, and weakness was present; severe LSD was scored if high fever (>400C), extensive 181 
nodular lesions/swellings, anorexia, weakness, emaciation or death was observed.  182 
Animal data including breed, sex, age and records like vaccination status, vaccination 183 
date and type of vaccine used were compiled for all animals at the first herd visit. Type of herd 184 
and sub-kebele were also recorded. The first visit was made by the district veterinary team and 185 
the first author. The animal health professionals who collected the data from infected animals 186 
were blind for the vaccination status of the affected animals. 187 
Biopsy samples of skin nodules were collected from a sample of the affected animals in 188 
each sub-kebele and analysed by conventional and Snapback Real-time PCR (polymerase chain 189 
reaction) techniques following the method described by Tuppurainen et al. (2005) and Gelaye 190 
et al. (2013) to confirm that the clinically observed disease truly was LSD. A total of 34 skin 191 
samples were collected for LSD confirmation. 192 
 193 
2.3.3. Vaccine used for control and prevention of LSD 194 
The live attenuated vaccine of KS1-O180 produced by National Veterinary Institute (NVI), 195 
Ethiopia was the only vaccine used for prevention and control of LSD in Ethiopia. It recently 196 
has been reported that the virus used for the production of KS1-O180 is not a sheep pox virus 197 
but was found to be LSDV (Gelaye et al., 2015). The vaccine was prepared in 20 ml vials 198 
containing 100 doses and reconstituted by 100 ml of cool and sterile saline water; 103.5 TCID50 199 
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was administered per animal as recommended by the manufacturer. A suspension of 1 ml 200 
vaccine was injected subcutaneously at the neck side (NVI, 2010 ). 201 
 202 
2.3.4. Data management and analysis  203 
Descriptive statistics were used to describe the morbidity and mortality in cattle populations 204 
with different vaccination coverage.  205 
To analyse the association between the occurrence of LSD infections in animals (i.e. the 206 
cases, which are assumed to be binomial distributed) and independent variables (vaccination 207 
status, breed, age, sex, herdtype, and location), multivariable logistic regression was performed 208 
(STATA version 14). Vaccination status was the main effect of interest while location, breed, 209 
age, sex and herdtype were added as additional explanatory variables. All factors were fitted in 210 
a multivariable regression model and the final model was obtained by a backward stepwise 211 
elimination procedure while checking for confounding. For that purpose confounding was 212 
defined as a change of at least 25% in any of the regression coefficients after removing a non-213 
significant (p>0.05) variable from the model. Interactions were tested for all combinations of 214 
the significant main effects. Generalised estimating equations (GEE, population averaged 215 
model) was run using herd as random effect. An exchangeable correlation structure was 216 
specified for the random effect and results were expressed as Odds ratio (OR) and its 95% 217 
confidence interval (CI).  218 
To estimate the effect of vaccination on the severity (mild, moderate or severe) of LSD, 219 
first a univariable and then multivariable (backwards elimination process) ordered logistic 220 
regression analysis was run by incorporating breed, age, sex, herdtype, and kebele as potential 221 
factor and retaining it in the model as confounder when necessary. The probability of a 222 
vaccinated or unvaccinated infected animal falling in either of the severity categories was 223 
computed using estimated coefficients and the associated cut points of the ordered logistic 224 
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regression analysis. Proportionality of odds across response categories was tested using the 225 
approximate likelihood-ratio test (omodel logit command in STATA version 14). 226 
Multivariable regression analysis using a generalized linear model (GLM) was 227 
performed to assess the effect of vaccination on the transmission of LSD by setting LSD 228 
infection of animals as binomial (yes/no) dependent variable and vaccination status (yes/no) 229 
and fraction of vaccinated among the infected (FracVaccI) as independent variables. The model 230 
was fit using the complementary loglog (cloglog) link function and log (number of infected 231 
animals/total number of animals per sub-kebele) as offset (Velthuis et al., 2003) using STATA 232 
version 14. The susceptibility and infectiousness coefficients obtained from the analysis were 233 
used to calculate the transmission parameters by inserting them into the formulae described in 234 
Table 1. Note that in this case we observed the total outbreak in the sub-kebele and thus the 235 
regression coefficient estimates pertain to the final size of the outbreak and thus we directly 236 
estimate the reproduction ratio R rather than the transmission rate parameter β. 237 
Vaccine efficacy for susceptibility (VEs) and infectiousness (VEi) were estimated using 238 
formula 1 and 2 as described by Halloran et al. (2010) and Aznar et al. (2011) and for this the 239 
four transmission parameters with their expression were defined (Table 1). 240 
𝑉𝑉𝑉𝑉𝑉𝑉 = 1 − �𝑅𝑅𝑅𝑅𝑅𝑅
𝑅𝑅𝑅𝑅𝑅𝑅
� = 1 − �𝑅𝑅𝑅𝑅𝑅𝑅
𝑅𝑅𝑅𝑅𝑅𝑅
�                                                          (1) 241 
𝑉𝑉𝑉𝑉𝑉𝑉 = 1 − �𝑅𝑅𝑅𝑅𝑅𝑅
𝑅𝑅𝑅𝑅𝑅𝑅
� =  1 − �𝑅𝑅𝑅𝑅𝑅𝑅
𝑅𝑅𝑅𝑅𝑅𝑅
�                                                          (2) 242 
A vaccine with an efficacy of 0 was considered as not effective whereas a value of 1 243 
was considered fully efficacious. Values of vaccine efficacies above 0.7 are considered ‘good’, 244 
whereas vaccine efficacies in the range of 0.3 to 0.7 are generally considered ‘reasonable’ 245 
(Halloran et al., 2010; Lu. et al., 2013). However, this interpretation of vaccine efficacy does 246 
not correspond to whether vaccination will reduce R so that R<1, because whether R<1 also 247 
depends on the R in the absence of vaccination. 248 
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 The reproduction ratio in vaccinated animals was calculated by multiplying the effects 249 
of vaccination on susceptibility (exp(coefficient of the independent variable Vaccination)), and 250 
on infectiousness (exp(coefficient of the fraction of vaccinated among the infected)) and the 251 
intercept of the regression model. Whereas R for unvaccinated was calculated from the 252 
exponent of the intercept only. 253 
 254 
3. Results    255 
3.1. Questionnaire survey 256 
Based on the herd owner’s response, the vaccination coverage at herd level was estimated to be 257 
56.3%. The public veterinary service vaccinated the majority (88.9%) of the herds and more 258 
than 95% of the herds did not get routine prophylactic vaccination against LSD but were 259 
vaccinated just after the LSD index case was reported in a neighbouring kebele. More than 60% 260 
of the herd owners deemed the vaccine to be of low to very low efficacy in protecting against 261 
clinical LSD, however, almost all of them responded that the vaccine did not induce any adverse 262 
reaction after vaccination (Table 2). 263 
 264 
3.2. Follow-up study 265 
3.2.1. Description of LSD occurrence and vaccination 266 
The follow-up study was undertaken in 10 sub-kebeles with 339 infected herds comprising a 267 
total of 2053 cattle of which 1304 (63.5%) were vaccinated (Table 3). Herd size varied from 1 268 
(n=6) to 37 (n=1) with an average of 6 and a median of 6 animals. About 95% of the herds had 269 
10 or less animals. The study population consisted of 346 (16.8%) calves, 263 (12.8%) heifers, 270 
227 (11.1%) bulls, 490 (23.9%) cows and 727 (35.4%) oxen. Of the 2053 animals, 526 (25.6%) 271 
were diagnosed with LSD, 233 (31.1%) in the unvaccinated group and 293 (22.5%) in the 272 
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vaccinated group (Chi-square test: p<0.001). The PCR results confirmed the LSD infection in 273 
all ten sub-kebeles.  274 
The multivariable population averaged model showed that herd did not contribute 275 
significantly to the total variance. Therefore multivariable logistic regression without random 276 
effects was performed which showed that the estimates and their significance were very similar 277 
to the random effects model. All variables remained significant in the multivariable analysis 278 
except herdtype but this variable confounded the estimates of location. Results show that 279 
vaccination significantly decreased the risk of LSD (OR= 0.49, 95% CI: 0.37; 0.64). 280 
Crossbreeds, males and older age were associated with increased risk to be LSD positive 281 
compared to their references and the interaction between vaccination and breed was significant. 282 
Vaccination is more efficient in crossbreed (OR= 0.49*0.43=0.21) than local breed (OR=0.49) 283 
animals (Table 4). 284 
 285 
3.2.2. LSD severity and vaccination 286 
The severity of LSD was assessed on a total of 480 clinically infected cattle (264 vaccinated 287 
and 216 unvaccinated). In unvaccinated animals, the majority of the affected animals (50.5%) 288 
were categorized as severe and 9.7% fell in the mild category whereas in vaccinated animals 289 
these figures were 42.8% and 17.1% respectively (Table 5). The results of the multivariable 290 
ordered logistic model showed that only vaccination was significantly associated with a 291 
different (lower) severity score (Odds Ratio (OR) = 0.68, 95% confidence interval (CI): 0.49; 292 
0.96). The test for the proportional odds assumption was not significant (p = 0.21) indicating 293 
that it is valid to report the OR as 0.68. Furthermore, the predicted fraction showed that the 294 
probability of developing moderate and severe disease was slightly higher in unvaccinated 295 
animals (0.89) compared to vaccinated animals (0.84). 296 
 297 
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3.2.3. LSD vaccine efficacy with respect to transmission 298 
The multivariable GLM analysis showed that both the susceptibility (exp(b) = 0.54, 95% CI: 299 
0.44; 0.66) and infectiousness (exp(b) = 1.83, 95% CI: 1.28; 2.61) effects of the vaccine are 300 
significant and thus the effects are a reduction in susceptibility by a factor 2 and an increase in 301 
infectiousness by a factor 2 (Table 6).  302 
A 0.46 vaccine efficacy for susceptibility and -0.83 for infectiousness recorded in this study 303 
were obtained by inserting the corresponding estimated partial reproduction ratios (Ruu = 1.21, 304 
Ruv = 0.65, Rvu = 2.22 and Rvv = 1.19) into formula 1 and 2 (Table 1 and 6).  305 
The estimated reproduction ratios for vaccinated and unvaccinated cattle were almost equal: 306 
1.19 (95% CI: 1.02-1.39) and 1.21 (95% CI: 1.01-1.46). The 0.98 (95% CI: 0.73-1.33) reduction 307 
in R by vaccination was not significantly different from 1 (p = 0.92). 308 
 309 
4. Discussion 310 
LSD vaccine breakdown and a concomitant morbidity are reported in Ethiopian cattle since 311 
1993 (Carn, 1993) while vaccination with KS1 O-180 vaccine is the major control method in 312 
the country. However, the efficacy of KS1 O-180 virus strain vaccine against natural LSD 313 
infections under field conditions and its impact on the transmission and severity of the disease 314 
is largely unknown and both are estimated in this paper. 315 
 316 
4.1. Questionnaire survey 317 
The questionnaire survey shows that in almost all study districts no regular vaccination program 318 
for LSD is applied. This is related to the long time (5 or more years) interval between LSD 319 
epidemics (Woods, 1988) and resource limitation. LSD vaccination is usually initiated by the 320 
appearance of an index case in an area. Therefore, vaccination for LSD is commonly carried 321 
out at the face of the outbreak to control the disease occurrence. However, vaccinating animals 322 
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during an outbreak may aggravate the transmission of LSD due to iatrogenic transmission from 323 
healthy looking, incubating animals to susceptible animals (Hunter and Wallace, 2001). The 324 
survey also showed that most of the vaccinations were provided by the public veterinary 325 
service. This clears out the suspect that the vaccine failure might be related to the administration 326 
of the vaccine by incompetent practitioners (and that apply LSD vaccination illegally).  327 
Vaccination coverage is an important issue in disease control. Cattle populations with 328 
low vaccination coverage are assumed to remain at higher risk for the disease. The 56.3% 329 
vaccination coverage at herd level estimated in this study is low given that the vaccine is 330 
provided free of charge. The reason for low coverage might be related to owner’s belief that the 331 
vaccine is not protective. More than 60% of the herd owners interviewed in the questionnaire 332 
survey reported low effectiveness of KS1 O-180 vaccine in protecting cattle against clinical 333 
LSD confirming the estimated poor performance of the vaccine (Ayelet et al., 2013; Gelaye et 334 
al., 2015). However, the low vaccination coverage is not related to vaccine adverse effects as 335 
almost all respondents did not indicate any adverse effect. This is in agreement with what 336 
Gelaye et al. (2015) reported for the vaccine. However, in other countries adverse reactions in 337 
cattle vaccinated with sheep pox and Neethling virus based vaccine have been reported like 338 
swelling on the injection site and developing active LSD (Weiss, 1968; Yeruham et al., 1994; 339 
Ben-Gera et al., 2015; Abutarbush et al., 2016). 340 
4.2. Follow-up study 341 
The 22.5% morbidity in vaccinated animals recorded in the follow-up study is comparable to 342 
23.8% morbidity reported in central Ethiopia in cattle vaccinated with Kenyan sheep pox 343 
vaccine strain (Ayelet et al., 2013). However, a much lower morbidity of 4.7% (Abutarbush, 344 
2014), 11% (Brenner et al., 2009) and 1.6% (Ben-Gera et al., 2015) were recorded in vaccinated 345 
cattle of Jordan and Israel. This difference might be attributed to the difference in the quality 346 
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of the vaccine used, vaccination coverage, management system, environment or climate 347 
difference of the areas where the animals are kept. 348 
The factors age group, breed, sex, herdtype and location were included into the logistic 349 
regression model to adjust the estimate of vaccination. The adjusted odds ratio for vaccination 350 
was 0.49 which indicates that vaccination is protective for LSD. Unvaccinated animals have 351 
2.04 (1/0.49) times higher odds to acquire LSD than vaccinated ones. The interaction between 352 
vaccination and breed was significant and it revealed that vaccination was more efficient in 353 
crossbreed (OR= 0.21) than local breed (OR=0.49) animals. This might be related with the more 354 
susceptibility nature of Holstein-Zebu cross to LSD than pure local Zebu animals (Davies 1991; 355 
OIE, 2010). Possible confounding factors which are not measured in this study include 356 
movement of animals and vector density. No animal movement restriction was applied in the 357 
study area; animals move freely from area to area. This practice was similar in all study kebeles 358 
and for both vaccinated and unvaccinated animals. Vector density is also assumed to be similar 359 
in all study kebeles because they are located in the same geographical area with similar weather 360 
conditions and altitude and on top of that they are all within the range of the insect flight zone.  361 
Vaccination was associated with less severe LSD symptoms. This finding is in 362 
agreement with the observation of Abutarbush (2014) who reported a considerable change in 363 
feed intake and milk production, fever, and a longer duration of illness in the majority of 364 
unvaccinated cattle as compared to vaccinated cattle. Hence, LSD vaccination reduces disease 365 
severity and as consequence it may prevent part of the production loss due to LSD. Increased 366 
vaccine dose is claimed to improve the protective efficacy of the vaccine. Ben-Gera et al. (2015) 367 
reported a low incidence (1.85%) in cattle vaccinated with a 10 fold increased dose of RM65 368 
vaccine. The regular vaccine dose used to immunize cattle against LSD in Ethiopia is 10 fold 369 
compared what used to immunize sheep and goat. For cattle, LSD vaccine contains 103.5 TCID50 370 
attenuated virus per field dose while for sheep and goat it is, 102.5 TCID50 per dose (NVI, 2010). 371 
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The vaccine efficacy of 0.46 as estimated for susceptibility is within the ‘reasonable’ 372 
efficacy range of 0.3 to 0.7 (Halloran et al., 2010; Lu et al., 2013).This indicates that vaccination 373 
reduces susceptibility to LSD 2.17 times (1/(1-0.54)). However, vaccinated infected animals 374 
are 1.83 times more infectious than unvaccinated infected ones. This is contradictory from what 375 
is expected from a vaccine. The increased infectiousness might be related with disease 376 
management practices. In the usual management practice, diseased animals are isolated and 377 
penned separately from healthy animals. However, the situation in vaccinated LSD affected 378 
animals is different, they are less diseased (not easily noticed) and thus remain longer in the 379 
herd (not isolated or removed) while they are infectious. This condition might be favourable 380 
for the transmission of the virus. Therefore, in this regard, animal disease management might 381 
contribute to increased infectiousness. However, this finding needs further investigation 382 
because the disease management and other factors which can influence the infectiousness were 383 
not under control. In general, the gain in decreasing susceptibility in vaccinated cattle is 384 
cancelled out by almost the same increment of infectiousness and this indicates that KS1 O-180 385 
vaccine is not effective in controlling LSD in cattle populations. The overall low efficacy of the 386 
vaccine substantiates the previous findings that vaccination against LSD does not provide 387 
protection from clinical disease (Ayelet et al., 2013; Abutarbush, 2014; Gari et al., 2015). Most 388 
LSD vaccines currently available, except the homologous Neethling vaccine, provide poor 389 
protection against LSD transmission (Brenner et al., 2009; Somasundaram, 2011; Tuppurainen 390 
et al., 2014; Ben-Gera et al., 2015), which is a challenge for the control of the disease. 391 
Although vaccinating cattle against LSD is considered the main control option in 392 
resource poor countries like Ethiopia, little is known about the effect of vaccination on the 393 
disease dynamics. In the current study, the estimated reproduction ratios were 1.21 and 1.19 for 394 
unvaccinated and vaccinated cattle, respectively. In both cases R is greater than 1 and confirms 395 
that LSD virus can spread in cattle populations, regardless of their vaccination status, and can 396 
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cause a major outbreak. This shows that vaccination with KS1 O-180 vaccine alone cannot 397 
eliminate the disease from a cattle population. Thus, a more competent LSD vaccine and other 398 
additional measures, like movement control, detection and removal of infected animals, are 399 
needed to bring the reproduction ratio to below 1.0. 400 
An observational study was chosen for this study because it is less costly and enables to 401 
assess the performance of the vaccine under real-life circumstances, including the complex and 402 
not easily controllable exposure to LSDV due to the insect vectors involved. Important 403 
confounders were measured and equal exposure risk of vaccinated and unvaccinated animals 404 
were assumed. Furthermore, the study design avoids the ethical problem of using a placebo 405 
when an approved vaccine is available (Torvaldsen and McIntyre, 2002).  406 
 Observational studies are prone to potential biases due to its uncontrolled nature. The 407 
biases may be related to selection, misclassification of cases, confounding factors, dealing with 408 
the impact of unknown or unmeasured factors (Dohoo et al., 2003), missing information, and 409 
non-comparability of groups. The distribution of potentially confounding variables among the 410 
study groups and other variables which were not considered might also be a source of bias. 411 
Another limitation to this study is related to the severity assessment; subjectivity might be 412 
somehow involved in allocating affected animals into different categories and on few occasions 413 
the observer might have been unblinded for the vaccination status of the animal because the 414 
owner might have complained about the poor efficacy of the vaccine. We assumed that 415 
exposure to infection was equal in both vaccinated and unvaccinated animals, that all important 416 
confounders were measured and adjusted for by the model used. Considering these limitations, 417 
the results reported here should be interpreted carefully.  418 
 419 
5. Conclusion 420 
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The results of our study showed that KS1 O-180 strain vaccine reduces susceptibility of cattle 421 
to LSD but it also increases infectiousness by about the same amount, partially because animals 422 
with less severe disease signs may remain undetected in the herd for longer periods. Generally, 423 
the vaccine has poor efficacy in protecting cattle populations against LSD, neither by direct 424 
clinical protection nor by reducing transmission. Therefore, the prevailing situation dictates the 425 
urgent need of a competent LSD vaccines development to control LSD in endemic countries 426 
and to halt its current spread to free countries and continents.  427 
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 567 
Table 1. The fitted model to estimate LSD transmission rates in cattle populations with 568 
different levels of vaccination coverage in Mota town and Hulet Ejju Enessie district of 569 
Ethiopia.  570 
 571 
Partial R 
value 
Log β = c0 + c1*vaccination + c2*fracVaccIa 
Description 
Expressionb 
Ruu Transmission from an unvaccinated to an unvaccinated animal ec0 
Ruv Transmission from an unvaccinated to a vaccinated animal ec0 + c1 
Rvu Transmission from a vaccinated to an unvaccinated animal ec0 + c2 
Rvv Transmission from a vaccinated to a vaccinated animal ec0 + c1 + c2 
a Fraction of vaccinated among the infected. 572 
b Relation between infection parameters and estimated coefficients of the model, where c0 is the estimated intercept and c1 and 573 
c2 are the estimated regression coefficients of the variables vaccination and fracVaccI respectively. 574 
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Table 2. Ethiopian herd owners’ opinion on LSD vaccine effectiveness and adverse reactions. 575 
 576 
Level Vaccine effectiveness Vaccine adverse reactions 
Frequency Percent Cum. percent Frequency Percent Cum. percent 
Very high 0 0 0 1 0.8 0.8 
High 29 23.2 23.2 1 0.8 1.6 
Moderate 20 16.0 39.2 0 0 1.6 
Low 6 4.8 44 0 0 1.6 
Very low 70 56.0 100 123 98.4 100 
Total 125 100 100 125 100 100 
  577 
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Table 3. LSD infection and death proportion in vaccinated and unvaccinated cattle population at different localities of Mota town and Hulet Ejju 578 
Enessie district of Ethiopia. 579 
  580 
  581 
 
Sub-
kebele/town 
Population Unvaccinated Vaccinated 
 
Total 
No. 
(Proportion) 
infected 
No. 
(Proportion) 
died 
 
Total 
No. 
(Proportion) 
infected 
No. 
(Proportion) 
died 
 
Total 
No. 
(Proportion) 
infected 
No. 
(Proportion) 
died 
Mota 169 40 (0.237) 2 (0.012) 87 26 (0.299) 2 (0.023) 82 14 (0.171) 0 (0.000) 
Akobe 108 22 (0.204) 0 (0.000) 74 14 (0.189) 0 (0.000) 34 8 (0.235) 0 (0.000) 
Atetanat 134 50 (0.373) 8 (0.060) 51 19 (0.373) 2 (0.039) 83 31 (0.373) 6 (0.072) 
Kesmender 145 35 (0.241) 2 (0.014) 38 9 (0.237) 0 (0.000) 107 26 (0.243) 2 (0.019) 
Komma 76 16 (0.211) 0 (0.000) 7 3 (0.429) 0 (0.000) 69 13 (0.188) 0 (0.000) 
Semo 220 54 (0.245) 0 (0.000) 214 53 (0.248) 0 (0.000) 6 1 (0.167) 0 (0.000) 
Shewaber 187 44 (0.235) 2 (0.011) 108 28 (0.259) 1 (0.009) 79 16 (0.203) 1 (0.013) 
Webmariam 432 109 (0.252) 8 (0.019) 127 64 (0.504) 4 (0.031) 305 45 (0.148) 4 (0.013) 
Yerez 430 125 (0.291) 7 (0.016) 23 10 (0.435) 2 (0.087) 407 115 (0.283) 5 (0.012) 
Zenabach 152 31 (0.204) 0 (0.000) 20 7 (0.350) 0 (0.000) 132 24 (0.182) 0 (0.000) 
Overall 2053  526 (0.256) 29 (0.014) 749 233 (0.311) 11 (0.015) 1304 293 (0.225) 18 (0.014) 
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 582 
Table 4. Multivariable analysis of potential riskfactors for LSD infection in Mota town and 583 
Hulet Ejju Enessie district of Ethiopia (n=2053) using logistic regression. 584 
 585 
Risk factor Category 
No. of 
animals 
No. 
LSD 
Odds Ratio 95% CI p-value 
Vaccination 
Vaccinated 1304 293 0.49 0.37-0.64 0.000 
Unvaccinated 749 233 Ref   
Breed 
Cross 312 95 3.83 2.25-6.53 0.000 
Local 1741 431 Ref   
Age group 
Calf 346 46 Ref   
Young 490 91 1.50 1.01-2.22 0.043 
Adult 1217 389 3.02 2.14-4.25 0.000 
Sex 
Male 1120 339 1.79 1.44-2.23 0.000 
Female 933 187 Ref   
Herdtype 
Specialized 126 28 0.53 0.22-1.27 0.157 
Mixed 1927 498 Ref   
Location 
Ayen Berhan 432 109 1.25 0.60-2.60 0.557 
Beza Bizuhan 564 175 2.12 1.02-4.00 0.044 
Debre Gubae 373 82 1.33 0.63-2.81 0.458 
Hibre Selam  515 120 0.80 0.38-1.66 0.545 
Mota town 169 40 Ref   
Interaction Vaccinated * cross breed  0.43 0.23-0.81 0.008 
  586 
31 
 
Table 5. LSD severity in vaccinated and unvaccinated cattle population (n= 480) of Ethiopia.  587 
 588 
Severity 
level 
Vaccinated Unvaccinated 
Number Proportion in  % Number Proportion in % 
Mild 45 17.1 21 9.7 
Moderate 106 40.2 86 39.8 
Severe 113 42.8 109 50.5 
Total 264 100 216 100 
 589 
  590 
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Table 6. Analysis of the effect of vaccination on susceptibility and infectiousness of LSD in 591 
Mota town and Hulet Ejju Enessie district of Ethiopia (n=2053) using GLM. 592 
 593 
 
Variable 
Susceptibility/
infectiousness 
Coefficient 
(b) 
Effect 
(exp(b)) 
 
95% CI 
 
p-value 
Vaccination Susceptibility -0.62 0.54 0.44; 0.66 0.000 
FracVaccIa Infectiousness 0.60 1.83 1.28; 2.61 0.001 
Constant  0.19 1.21 1.00; 1.46 0.045 
aFraction of vaccinated among the infected in each population (= sub-kebele). 594 
 595 
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 611 
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 616 
 617 
Figure 1. Map of Ethiopia showing the area where the questionnaire survey was performed. 618 
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 633 
Figure 2. Map of Hulet Ejju Enessie district (Ethiopia) showing LSD vaccine efficacy 634 
observational study site. 635 
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